In a case series of five children with treatment-refractory neuroblastoma, it was feasible to manufacture and administer donor-derived GD2-specific CAR T cells and clinical responses were seen in four patients.
- Concetta Quintarelli
- Francesca Del Bufalo
- Franco Locatelli